Appendix A: MEDLINE, ERIC, PsycInfo and Healthstar Search Strategies

MEDLINE – CNS search

1. exp Infant, Low Birth Weight/
2. low birth weight.tw.
3. exp Infant, Premature/
4. 1 or 2 or 3
5. exp infant, low birth weight/ or exp infant, premature/
6. (small for gestational age or SGA).tw.
7. (preterm infant$ or infant or prematur$ or newborn).tw.
8. disab$.af.
9. limitation$.af.
10. handicap$.af.
11. impair$.af.
12. follow-up studies/
13. follow-up.tw.
14. exp Case-Control Studies/
15. case-control.tw.
16. exp Longitudinal Studies/
17. longitudinal.tw.
18. exp Cohort Studies/
19. cohort.tw.
20. (random$ or rct).tw.
21. exp Randomized Controlled Trials/
22. exp random allocation/
23. exp Double-Blind Method/
24. exp Single-Blind Method/
25. randomized controlled trial.pt.
26. clinical trial.pt.
27. (clin$ adj trial$).tw.
28. ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).tw.
29. exp PLACEBOS/
30. placebo$.tw.
31. exp Research Design/
32. Comparative Study/
33. exp Evaluation Studies/
34. exp Prospective Studies/
35. 5 or 6 or 7
36. 35 and (8 or 9 or 10 or 11)
37. limit 36 to (clinical trial or clinical trial, phase ii or clinical trial, phase iii or clinical trial, phase iv or controlled clinical trial or guideline or meta analysis or practice guideline or randomized controlled trial or review or review literature or review, academic or review, multicase or review, tutorial)

38. 36 and (12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34)
39. 37 or 38
40. limit 39 to human
41. limit 40 to english language
42. neuro$.tw.
43. white matter damage.tw.
44. exp intracranial hemorrhages/ or exp leukomalacia, periventricular/
45. exp Retinopathy of Prematurity/
46. ROP.tw.
47. 43 or 44
48. 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34
49. 2 or 5 or 6 or 7
50. 48 and 49 and 47
51. 42 or 43 or 44
52. 48 and 49 and 51
53. limit 50 to (addresses or bibliography or biography or comment or dictionary or directory or editorial or festschrift or guideline or lectures or legal cases or letter or meta analysis or news or periodical index or practice guideline or review or review literature or review of reported cases or review, academic or review, multicase or review, tutorial)
54. 52 not 53
55. limit 54 to human
56. limit 55 to english language

Eric search

1. follow-up studies/
2. follow-up.tw.
3. exp Case-Control Studies/
4. case-control.tw.
5. exp Longitudinal Studies/
6. longitudinal.tw.
7. exp Cohort Studies/
8. cohort.tw.
9. (random$ or rct).tw.
10. exp Randomized Controlled Trials/
11. exp random allocation/
12. exp Double-Blind Method/
13. exp Single-Blind Method/
14. randomized controlled trial.pt.
15. clinical trial.pt.
16. (clin$ adj trial$).tw.
17. ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).tw.
18. exp PLACEBOS/
19. placebo$.tw.
20. exp Research Design/

21. Comparative Study/
22. exp Evaluation Studies/
23. disab$.af.
24. exp disabilities/
25. limitation$.af.
26. handicap$.af.
27. impair$.af.
28. exp PHYSICAL DISABILITIES/ or exp SEVERE DISABILITIES/ or exp DEVELOPMENTAL DISABILITIES/ or exp LEARNING DISABILITIES/ or exp MILD DISABILITIES/ or exp MULTIPLE DISABILITIES/
29. (small for gestational age or SGA).tw.
30. exp birth weight/
31. exp premature infants/
32. (preterm infant$ or infant or prematur$ or newborn).tw.
33. 23 or 24 or 25 or 26 or 27 or 28
34. 33 and (29 or 30 or 31 or 32)
35. 34 and (1 or 2 or 4 or 6 or 8 or 9 or 16 or 17 or 19 or 20 or 21)

GI search

174. exp enterocolitis/
175. exp cholestasis/
176. exp short bowel syndrome/
177. enterocolitis$.tw.
178. NEC.tw.
179. necrot$.tw.
180. (Total parenteral nutrition or TPN).tw.
181. cirrhosis.tw.
182. (gastrostomies or GERD or Fundoplication).tw.
183. short bowel syndrome.tw.
184. cholestasis.tw.
185. short gut.tw.
186. necrotizing.tw.
187. exp cirrhosis/

Health Care

174. rehospitalization.af.
175. costs.af.
176. costs.tw.
177. physical therapy.af.
178. exp *Occupational Therapy/
179. exp *Physical Therapy/
180. orthopedic.tw.
181. occupational therapy.af.
189. Health care resource.mp. or utilization.af. [mp=title, abstract, registry number word, mesh subject heading]
190. arthopedic.af.

191. orthopedic.af.

Healthstar

1. exp infant, low birth weight/ or exp infant, premature/
2. (small for gestational age or SGA).tw.
3. (preterm infant$ or infant or prematur$ or newborn).tw.
4. disab$.af.
5. limitation$.af.
6. handicap$.af.
7. impair$.af.
8. follow-up studies/
9. follow-up.tw.
10. exp Case-Control Studies/
11. case-control.tw.
12. exp Longitudinal Studies/
13. longitudinal.tw.
14. exp Cohort Studies/
15. cohort.tw.
16. (random$ or rct).tw.
17. exp Randomized Controlled Trials/
18. exp random allocation/
19. exp Double-Blind Method/
20. exp Single-Blind Method/
21. randomized controlled trial.pt.
22. clinical trial.pt.
23. (clin$ adj trial$).tw.
24. ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).tw.
25. exp PLACEBOS/
26. placebo$.tw.
27. exp Research Design/
28. Comparative Study/
29. exp Evaluation Studies/
30. exp Prospective Studies/
31. 1 or 2 or 3
32. 31 and (4 or 5 or 6 or 7)
33. limit 32 to (clinical trial or clinical trial, phase ii or clinical trial, phase iii or clinical trial, phase iv or controlled clinical trial or guideline or meta analysis or practice guideline or randomized controlled trial or review or review literature or review, academic or review, multicase or review, tutorial)
34. 32 and (8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30)
35. 33 or 34
36. limit 35 to human
37. limit 36 to english language
38. limit 37 to nonmedline

Immune

174. exp *Immunologic Diseases/ or exp *Autoimmune Diseases/ or exp *Collagen Diseases/ or exp *Immunologic Deficiency Syndromes/

Perinatal

174. antenatal steroid.tw.
175. Chorioamnioni$.tw.
176. chorionic villous sampling.tw.
177. diabet$.tw.
178. pre-eclamp$.tw.
179. 174 or 175 or 176 or 177 or 178

PsycInfo

1. follow-up studies/
2. follow-up.tw.
3. exp Case-Control Studies/
4. case-control.tw.
5. exp Longitudinal Studies/
6. longitudinal.tw.
7. exp Cohort Studies/
8. cohort.tw.
9. (random$ or rct).tw.
10. exp Randomized Controlled Trials/
11. exp random allocation/
12. exp Double-Blind Method/
13. exp Single-Blind Method/
14. randomized controlled trial.pt.
15. clinical trial.pt.
16. (clin$ adj trial$).tw.
17. ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$ or mask$)).tw.
18. exp PLACEBOS/
19. placebo$.tw.
20. exp Research Design/
21. Comparative Study/
22. exp Evaluation Studies/
23. exp Prospective Studies/
24. exp Premature Birth/
25. exp birth weight/
26. (small for gestational age or SGA).tw.
27. (preterm infant$ or infant or prematur$ or newborn).tw.
28. exp DISABILITY EVALUATION/
29. exp disabled/
30. disab$.af.
31. limitation$.af.
32. exp Mentally Retarded/
33. exp Behavior Problems/

34. exp communication skills/
35. handicap$.af.
36. impair$.af.
37. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23
38. 24 or 25 or 26 or 27
39. 37 and 38
40. 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36
41. 39 and 40
42. 38 and 40
43. limit 42 to ("0840 follow up study" or "0850 longitudinal study" or "0860 treatment outcome study" or "0900 errata/retractions" or 1300 literature review/research review or 1400 meta-analysis)
44. 41 or 43
45. limit 44 to human
46. limit 45 to english language

ROP
174. (retinopathy of prematur$ or POP).tw.
175. exp retinopathy of prematur$/ or POP/
176. (visu$ impair$ or blindness).tw.
177. Hypoxic-Ischemic encephalopathy.tw.

Acuity
174. SNAP.tw.
175. CRIB.tw.
176. 174 or 175

Audiology
174. Lasix.tw.
175. exp lasix/
176. hearing disorder$.tw.
177. aminoglycosides.tw.

Infection
174. RSV.tw.
175. exp meningitis/
176. meningitis.tw.
177. exp sepsis/
178. (sepsis or septic).tw.
179. congenit$.tw.
180. acquired.tw.

Lung dz
174. chronic lung disease$.tw.
175. Bronchopulmonary dysplasia$.tw.

176. asthma$.tw.
177. exp asthma/
178. pulmonary function$.tw.
179. tracheostomy.tw.
180. upper airway.tw.
181. reactive airway.tw.
182. exercise tolerance.tw.
183. exp upper airway/
184. exp tracheostomy/
191. exp *Lung Diseases/ or exp *Hypertension, Pulmonary/ or exp *Lung Diseases, Obstructive/ or exp *Bronchopulmonary Dysplasia/
192. upper airway.af.
193. asthma.af.
194. pulmonary function$.af.

Medication
174. dexamethasone.tw.
175. 50-02-2.rn.
176. dexamethasone.af.

Nutrition
174. exp nutrition/
175. nutrition.tw.
176. growth disorder$.tw.
177. exp growth disorder$/
184. exp Child Nutrition Disorders/
185. exp PARENTERAL NUTRITION, TOTAL/ or exp INFANT NUTRITION DISORDERS/

Appendix B: Data Abstraction Form

Low Birth Weight and Prematurity Association with Disability

Version 11b (10/14/02)

Instructions: Circle or fill-in where appropriate Only one answer except where indicated by an *

Reviewer: __ _____ Review date: ____/_____/____

First author:_____ Year:_____ UI:_____

STUDY CHARACTERISTICS

***Country:** **US** **UK** **Canada** **Other** _____ **N.D.**

Number of Sites: _____ **N.D.**

METHODOLOGY

Study Design (CHOOSE ONE):

, **Randomized Controlled Trial**

Non-randomized Comparison Trial

, **Prospective (Single arm) Cohort**

Retrospective Cohort

, **Case Series (Retrospective)**

, **Case –control (Retrospective)**

STUDY POPULATION

Year of birth of population
From_____ to _____

Inclusion criteria: _____

_____ _____

_____ _____

_____

Exclusion criteria: _____

_____

_____

Applicability of study sample to population of interest:

I. Sample representative of whole population with very low birth weight or premature infants

II. Sample is a relevant sub-group of whole population

III. Narrow sample, with limited applicability to study populat

If **II** or **III**, Why not **I**:

DEMOGRAPHICS OF INITIAL POPULATION (A)

	Sample 1	Sample 2
Description of group		
N		
Mean Age at entry (range)		
Mean GA (range)		
Mean BW (range)		
Male (%):		
Race (%):		
Other:		
Other:		

Comments:_____

_____

_____

DEMOGRAPHICS OF DIFFERENT FOLLOW-UP OR SUBGROUP POPULATION :

Other:		

B: Time of Evaluation:_____

	Sample 1	Sample 2
Description of group		
N		
Mean Age at eval (range)		
Mean GA (range)		
Mean BW (range)		
Male (%):		
Race (%):		
Other:		
Other:		

D: Time of Evaluation:_____

	Sample 1	Sample 2
Description of group		
N		
Mean Age at eval (range)		
Mean GA (range)		
Mean BW (range)		
Male (%):		
Race (%):		
Other:		

C: Time of Evaluation:_____

	Sample 1	Sample 2
Description of group		
N		
Mean Age at eval (range)		
Mean GA (range)		
Mean BW (range)		
Male (%):		
Race (%):		
Other:		
Other:		

E: Time of Evaluation:_____

	Sample 1	Sample 2
Description of group		
N		
Mean Age at eval (range)		
Mean GA (range)		
Mean BW (range)		
Male (%):		
Race (%):		
Other:		
Other:		

PREDICTORS OF DISBILITY EXAMINED

I

**General Predictors of Disability Examined:*

A) **Birth weight**

B) **GA**

C) **SGA/IUGR**

D) **Maternal disease**

E) **Antenatal steroids**

F) **Chronic illness**

G) **Cord pH**

H) **Apgar score**

I) **Illness severity**

J) **Intrauterine substance abuse (Opiates, Cocaine, Ethanol. Other_____)**

K) **Other:_____**

II **CNS Predictors of Disability Examined:*

A) **Intracranial/Intraventricular hemorrhage**

B) **White Matter Disorder**

C) **Periventricular leukomalacia**

D) **Ventriculomegaly/ Ventricular Dilation**

E) **Neurological feeding disorder /Swallowing**

F) **Seizures**

G) **Hypoxic-Ischemic Encephalopathy (HIE)**

H) **Indomethacin**

I) **Other:_____**

*III *Ophthalmology Predictors of Disability Examined:*

A) **Retinopathy of Prematurity (ROP)**

B) **Other:_____**

*IV *Audiology Predictors of Disability Examined:*

A) **Aminoglycosides**

B) **Furosemide**

C) **Hearing screen failure**

D) **Other:_____**

V **Cardiovascular or Pulmonary Predictors of Disability Examined:*

A) **Chronic Lung Diseases**

B) **Bronchopulmonary dysplasia**

C) **Other:_____**

*VI *Gastrointestinal Predictors of Disability Examined:*

A) **Short gut**

B) **Necrotizing "enterocolitis"**

C) **Total Patenteral Nutrition**

D) **Cholestasis**

E) **Other:_____**

*VII *Other Predictors of Disability Examined:*

A) **Nutrition / Growth**

B) **Infectious disease**

C) **Immune Disorders**

D) **Hospital / Health care resource utilization**

E) **Illness Acuity**

F) **Dexamethasone**

G) **Perinatal Factors**

H) **Osteomalacia**

I) **Other:_____**

J) **Other:_____**

K) **Other:_____**

How predictors defined/measured:

_____

_____

_____

_____ ND

Are the definitions correct/ appropriate? Y N **If No, Why not?**_____

_____

_____

_____

OUTCOMES EXAMINED

I ****CNS Outcomes Examined:***

A) Motor delay
B) Cerebral palsy
C) Cognitive delay
D) Mental retardation
E) Behavioral disorders
F) School problems
G) Learning disabilities
H) Seizure disorder
I) Post Hemorrhagic Hydrocephalus (PHH)
J) Other: _____

II ****Ophthalmology Outcomes Examined:***

A) Visual impairment
B) Blindness
C) Other: _____

III ****Audiology Outcomes Examined***

A) Hearing disorders
B) Deafness
C) Speech
D) Language
E) Communication disorder
F) Other: _____

IV ****Pulmonary Outcomes Examined***

A) _____
B) _____

V ****Growth Outcomes Examined***

A) _____
B) _____

VI ****GI Outcomes Examined***

A) _____
B) _____

VII ****Other Outcomes Examined***

A) _____
B) _____

Definition of Outcomes Used by Author (methods of measure):

_____

_____

_____

_____

_____

N.D.

Are the definitions correct/ appropriate?

, **Unable to evaluate** , **Yes**

, **No**

If no, why ?

_____

_____

_____

_____

_____

RESULTS:

Group	Predictor Category	Predictors/Conditions	N	Outcome Category	Outcome of Interest/ Instruments used	% (or n/N) with Outcome	Methods of Correlation

RESULTS (cont'd):

Group	Predictor Category	Predictors/Conditions	N	Outcome Category	Outcome of Interest/ Instruments used	% (or n/N) with Outcome	Methods of Correlation

Bias Limitation::

_____
_____
_____
_____
_____
_____
_____
_____
_____
_____
_____
_____
_____
_____
_____
_____

Internal Validity (Quality of Methods)

A Prospective (Not Retrospective). Complete reporting of methods and results (incl. inclusion/exclusion criteria, "Table 1 data,") proper reference ("gold") standard, correct analyses performed (No data inconsistency and discrepancy).

B Prospective or Retrospective. Not all criteria of A. Some deficiencies, however, unlikely to cause major bias

C Prospective or Retrospective. Significant design or reporting errors, large amount of missing information or bias. No reference standard provided or use of inappropriate reference standard.

If B or C: **Deficiency:**

_____

General instructions for LBW data extraction:

The form has been designed to collect all the relevant information from each article. The data on the form will allow us to fully evaluate each study's population, basic methods, relevant results (relevant for the SSA project), applicability to other children with the condition of interest, and overall quality.

For each line (or section), please circle the appropriate answer to the question (in bold) or fill in the data on the lines provided. Questions proceeded by an * can have multiple answers (such as study performed in UK and France). Please circle "N.D (no data)." if the answer to the question is not provided (eg, if information on the age of the subjects is not provided).

Study Characteristics: Self-explanatory for Country and number of sites.
Length of Following up time: Enter corrected age and average duration.
Corrected age mean: age from the obstetric due date to follow-up evaluation date.

Demographics: Enter all relevant demographic information when provided (eg, mean, standard error and range).
If median is provided, cross out mean and write in median.
For weight, please fill in the relevant data as reported in the article.
For gender and race, fill in the percentages (or the fraction).

Study population: Enter inclusion and exclusion criteria (may need to check abstract, results, and discussion sections for completeness).

Enter total number of subjects with low birth weight enrolled (including those eventually excluded or who withdrew, etc.). If only the number of subjects evaluated is reported, circle N.D.
Enter final sample size (the total number of subjects with low birth weight evaluated)
Enter total number of control subjects (presumably of normal Birth weight) enrolled and evaluated.
If reported, list reasons for withdrawal, etc. (Consider this in the assessment of possible bias later on.)

Assess **Applicability** of study to population of interest:

Consider all the data that has just been entered (study characteristics, demographics, inclusion/exclusion criteria, sample size, number and reasons for withdrawal) to determine how applicable the study is to the population of interest to us. Note that this may be a different population than the population of interest to the study authors.

First circle the question that the study is most relevant for.

Then choose one of the categories:

Category I. If sample is representative of the whole population of babies with prematurity and low birth weight condition relevant to the topic question (eg, whole population of preterm babies and infants with BW 1200-2000g). This implies a reasonable sample size, a diverse group of infants with the condition, and inclusion/exclusion criteria that will capture the whole group. Consider both who the study aimed to recruit and also who they actually included.

Category II. A relevant sub-group or subgroups of very low birth weight and prematurity, (only those with a specific, though common, condition eg: BW 1200-1500g).

Category III. A very narrow group of subjects who are a limited sample of very low birth weight and prematurity (only those with a relatively rare condition, or a non-representative demographic group e.g. crack babies)).

If Category II or III chosen, please indicate reason not in Category I (i.e., why not fully generalizable)

Methodology:

Study design: Provide one answer per line:
What is study design? (For RCT, ensure that authors state "randomized"). Prospective or retrospective cohort studies, retrospective case-control and case series may have one or more arms (i.e. treatment vs placebo).

Predictors of Disability Examined

Please circle or write in the predictors of disability that were examined in the study. These can include the factors or combination of factors predict future disability in the low birth weight and prematurity babies.

Note that the study might not clearly list the predictors evaluated. You may need to check the methods, results and discussion section to figure this out.

If provided, give the definitions the authors used for the various predictors. This may be as simple as Birth weight 1200 gms, or it may be a detailed description of their definition of HIE. This can be kept succinct.

Are the definitions used appropriate?

Outcomes Examined

Similar to predictors, circle or write in the outcomes examined.
Not all examined outcomes are necessary. Include only those that are relevant to the Topic question).
Define outcomes and determine appropriateness.

Results

The tables provided should be able to accommodate most (hopefully all) studies. Even if no statistical analysis was done by the authors, the table should be completed.

Each row will represent specific condition/predictor combination.

In a study with these four groups of subjects, each group would be put on a separate row in the first column of the table.

For each condition/predictor put the number of subjects evaluated in the second column.

In each row, write in the specific outcome evaluated. Each different outcome of interest should have its own row, or group of rows, write the instruments that being used. (How to measure outcome).

In the fourth column, give the results. What percentage of subjects in each group had the outcome of interest. You can also enter the fraction (or number of subjects), if that is easier. If other results are reported (such as odds ratio (OR)) write that in. However, please clarify what the outcome being reported is, if it's not percentage.

If there were results that are of interest, that do not conform to the table, write them in below.

Biases/Limitations:

Write down biases or limitations

Quality of Methods:

Grade quality of study (methods and reporting, not results) in 3 categories, A, B, or C.
Consider methods, definitions used, statistical analyses done, biases, etc.

A: Prospective study that is clearly reported, uses explicit and appropriate eligibility criteria, uses appropriate definitions of predictors and outcomes that are properly measured or estimated, uses appropriate statistical and analytical methods, and is free of obvious bias. Retrospective studies, irrespective of other aspects of quality, cannot be in category A. Study size should not be a factor for quality.

B: Prospective or retrospective study that does not meet qualifications of category A but deficiencies are unlikely to cause major bias.

C: Major deficiencies that cannot exclude possibility of significant bias. Insufficiently reported information.

If B or C, indicate briefly what the deficiency or deficiencies are in the paper.

Please check data information:

Check abstract numbers, tables, results and discussion for discrepancy (e.g. add them all

Appendix C: Acronyms and Abbreviations

AA	Arachidonic acid
AGA	Appropriate for gestational age
ADIT	Auditory discriminating test
BPD	Bronchopulmonary dysplasia
BSCP	Bilateral spastic cerebra palsy
BWVK	Bourdon-Wiersma-Vos concentration test for infants
BW	Birth weight
CBCL	Child Behavior Check List
CLD	Chronic lung disease
CNS	Central Nervous System
CP	Cerebral Palsy
CRIB	Clinical Risk Index for Babies
CRYO ROP	Multicenter Trial of Cryotherapy for ROP
dBHL	Decibels
DHA	Docosahexaenoic acid
DDST	Development Screening test
DQ	Developmental quotient
DR-CPR	Delivery room resuscitation
EHM-T	Exclusively human milk-fed until term CA
ELBW	Extremely Low Birth Weight
GA	Gestational age
GM	Isolated germinal matrix hemorrhage
IBR	Infant behavior record
ICH	Intracranial hemorrhage
IQ	Intelligence quotient
IUGR	Intrauterine growth retardation
IVH	Intraventricular hemorrhage
LBW	Low Birth Weight
MDI	Mental Development Index
MR	Mental Retardation
NBRS	Neurobiologic Risk Score
NBW	Normal Birth Weight
NCHS	National Center for Health Statistics
ND	No data
NEC	Necrotizing enterocolitis
NICHD	National Institute of Child Health and Development
NICU	Neonatal Intensive Care Unit
NS	Not significant
PDA	Patent ductus arteriosus
PDI	Psychomotor Developmental Indexes
PEV	Periventricular echodensities
PL	Parenchymal lesions
PMA	Postmenstrual age

PPVT	Peabody Picture Vocabulary Test
PROM	Premature rupture of membranes
PVL	Periventricular leukomalacia
RCP	Revised Class Play
RDS	Respiratory distress syndrome
ROP	Retinopathy of Prematurity
SGA	Small for gestational age
SNHL	Sensorineural hearing loss
TRF	Teacher Report Form
US	Ultrasound
VE	Ventricular enlargement
VLBW	Very Low Birth Weight
VMI	Visual-motor integration test
VM	Ventriculomegaly
WISC-R	Wechsler Intelligence Scale for Children-Revised
WMD	White Matter Damage
WPPSI	Wechsler Preschool and Primary Scale of Intelligence

Appendix D. Acknowledgments

The Evidence-based Practice Center staff acknowledges the collaboration of the clinical experts who served on the EPC Technical Expert Panel. The EPC also acknowledges the contributions by those who acted as peer reviewers for the evidence report.

New England Medical Center EPC Project Staff

Joseph Lau, MD; EPC/Project Director
Ethan Balk, MD, MPH, Assistant Project Director and Project Leader, Short Stature
Cynthia Cole, MD, MPH, Coordinating Team Leader
Deirdre DeVine, M Litt, Project Manager
Priscilla Chew, MPH, Project Leader, Failure to Thrive
Kimberly Miller, BA, Research Assistant
Chenchen Wang, MD, MSc, Project Leader, Low Birth Weight

Technical Expert Panel

Evidence Review Teams, Tufts New England Medical Center

Very Low Birth Weight:
Dr. Cynthia Cole, Project Coordinator and Team Leader
Drs. Geoffrey Binney, John Fiascone, James Hagadorn, and Chiwan Kim
Patricia Casey, NNP

Short Stature: Dr. Patricia Wheeler, Team Leader
Drs. Barbara Shephard and Karen Bresnahan

Failure To Thrive: Dr. Ellen Perrin, Team Leader
Drs. Stephan Glicken, Nicholas Guerina, Kevin Petit, Robert Sege, MaryAnn Volpe, and Deborah Frank

James Perrin, MD, Pediatric Consultant to the EPC

Social Security Administration (SSA):

Science Partner: Dr. Paul Burgan, MD, PhD; Regina Connell, MS

Agency for Healthcare Research and Quality (AHRQ)

Marian James, PhD, Task Order Officer

American Academy of Pediatrics

Marilee Allen, MD (Very Low Birth Weight)
Professor
Neonatology, Department of Pediatrics
Johns Hopkins University
Baltimore, Maryland

Joseph Hersh, MD (Short Stature)
Louisville, Kentucky

Michael Farrell, MD (Failure to Thrive)
Chief of Staff
Children's Hospital Medical Center
Cincinnati, Ohio

Carla Herrerias, BS, MPH
Senior Health Policy Analyst
Department of Practice and Research
American Academy of Pediatrics
Elk Grove Village, Illinois

Disability Law Center, Inc.
Linda Landry, Esq.

Peer Reviewers

American Academy of Pediatrics

Very Low Birth Weight

Deborah Campbell, MD
Hartsdale, New York

Warren N. Rosenfeld, MD
Department of Pediatrics
Winthrop University Hospital
Mineola, New York

Short Stature

Susan Rose, MD
Department of Endocrinology
Children's Hospital Medical Center of Cincinnati
Cincinnati, Ohio

Failure to Thrive

William Cochran, MD
Department of Pediatric GI/Nutrition
Geisinger Health System
Danville, Pennsylvania

American Association of Clinical Endocrinologists

A. Jay Cohen, MD
The Endocrine Clinic, PC
Memphis, Tennessee

Lawson Wilkins Pediatric Endocrine Society

David M. Brown, MD
Professor of Pediatrics
University of Minnesota
Minneapolis, Minnesota

National Institute of Child Health and Human Development

Gilman Grave, MD (for Short Stature)
Chief, Endocrinology, Nutrition and Growth Branch
Center for Research for Mothers and Children
Bethesda, Maryland

Catherine Y. Spong, MD (for VLBW and Failure to Thrive)
Chief, Pregnancy and Perinatology Branch
Center for Research for Mothers and Children
Bethesda, Maryland

Tonse Raju, MD (for VLBW and Failure to Thrive)
Pregnancy and Perinatology Branch
Center for Research for Mothers and Children
Bethesda, Maryland

Society for Developmental and Behavioral Pediatrics

Denis Drotar, MD
Professor and Chief
Division of Behavioral Pediatrics and Psychology
Rainbow Babies and Children's Hospital
Cleveland, Ohio

Daniel Kessler, MD
Phoenix, Arizona